Key Findings
The North America market for nasal spray devices finds their applications predominantly in the healthcare sector to treat various diseases such as allergic, respiratory and chronic obstructive pulmonary diseases. The North America market is estimated to advance at a CAGR of 6.81% during the forecast years of 2019-2027.

Market Insights
The North America market is said to be on an upsurging end due to the massive investments by the government in the development of new and innovative nasal spray products along with a high incidence of asthma and other respiratory diseases.

The United States and Canada are considered for the market study. The high incidence of asthma and other respiratory diseases are expected to create lucrative growth opportunities for the nasal spray devices market across the United States. Canada nasal spray devices market is primarily driven by a high number of deaths due to air pollution coupled with ongoing clinical trials on nasal spray devices in the country.

Competitive Insights
The major contending players operating in the nasal spray devices market that are mentioned in the report are Merck & Co., Inc., Apotex, Mylan NV, Adapt Pharma, Inc. (acquired by Emergent BioSolutions), Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, Hikma Pharmaceuticals PLC, Pfizer, Inc., Becton Dickinson and Company, Allergan Inc., Sandoz International GmbH (subsidiary of Novartis AG), Sun Pharmaceuticals Industries, Ltd., Beximco Pharmaceuticals, Sanofi-Aventis S.A. and Cipla.